SecBot SecBot
S-3 ·Filed Apr 3, 2026

RLMD

RELMADA THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed7mo ago SEC0001213900-26-039967
Shelf registration, potential dilution
Actionable Insight • Neutral

This is a routine shelf registration following a recent capital raise. The lack of company proceeds and recent strong financing suggest this is administrative, not a sign of immediate fundraising need. Monitor for actual issuance under the shelf, which could create dilution.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.90
T+0 close · Apr 3, 2026 · via day close
Latest settled
−7.39%
T+60 · $6.39
Vs SPY
−20.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $6.90entry
  2. T+1 · 7mo ago −2.17%α −2.24% · $6.75
  3. T+5 · 7mo ago +6.96%α +2.82% · $7.38
  4. T+20 · 7mo ago +7.39%α −1.59% · $7.41
  5. T+60 · 5mo ago −7.39%α −20.86% · $6.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relmada Therapeutics filed an S-3 shelf registration to register the resale of 33,685,096 shares of common stock by selling stockholders, including 29,474,569 shares and 4,210,527 shares issuable upon exercise of pre-funded warrants, from a recent $160 million PIPE financing. The company will not receive proceeds from the resale, but the registration supports future capital raising flexibility. This follows strong clinical data for NDV-01 and a robust cash position extending into 2029.

Key Financial Metrics

Offering Size
$160.0M

Key Facts

  • S-3 shelf registration filed for resale of 33,685,096 shares by selling stockholders from a March 2026 PIPE financing
  • Offering includes 29,474,569 shares of common stock and 4,210,527 shares issuable upon exercise of pre-funded warrants
  • Total offering value registered is $215.9 million based on a $6.41 share price
  • Company will not receive any proceeds from the resale of shares by selling stockholders
  • Recent $160 million PIPE financing completed in March 2026 strengthens cash position to fund operations through 2029
  • Positive 12-month Phase 2 data for NDV-01 in bladder cancer showed 76% durable complete response rate

Financial Impact

The registration covers $215.9 million of shares for resale, but the company receives no proceeds. The recent $160 million PIPE financing provides significant capital.

dilutioncash

Risk Factors

  • Future issuance under the shelf could lead to shareholder dilution
  • Biotech clinical development carries inherent risks of trial failure
  • Pre-funded warrants could be exercised, increasing share count

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 11 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001213900-26-039967
Document: ea028291501ex-fee.htm0001213900-26-039967
Document: ea028291501ex5-1.htm0001213900-26-039967
Document: ea028291501ex23-1.htm0001213900-26-039967
Document: ea028291501ex23-2.htm0001213900-26-039967
Document: ea028291501ex3-1v.htm0001213900-26-039967
Document: ea028291501ex3-1vi.htm0001213900-26-039967
Document: ea028291501ex3-1vii.htm0001213900-26-039967
Document: 0001213900-26-039967-index-headers.html0001213900-26-039967
Document: 0001213900-26-039967-index.html0001213900-26-039967
Document: 0001213900-26-039967.txt0001213900-26-039967

Track record

11 reports on RLMD

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
  4. Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
  5. May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
  6. May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
  7. Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
  8. Apr 3, 202632w ago S-3 Neutral 3/10 Viewing Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
  9. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
  10. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026